Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer

Inclusion Criteria: * Female patients with recurrent or metastatic TNBC, as confirmed by histological or cytological examination * Age 18-70 years old * According to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, there is at least one measurable lesion. * The Eastern Cooperative Oncology Group (ECOG) scores 0-2 * Expected survival ≥ 12 weeks * Negative for ER/PR * All patients will be tested for bone marrow capacity, liver and renal functions within 7 days prior to enrollment * Previous use of anthracyclines and/or taxanes * The medication history of vinorelbine * Female patients of childbearing age must take adequate contraception; otherwise the patients must be proven to be infertile * No history of serious heart, lung, liver, and kidney diseases * Provision of written informed consent Exclusion Criteria: * Patients who receive chemotherapy, radiation therapy, targeted drugs, or hormone therapy within 3 weeks of administration * Patients using corticosteroids for untreated brain or subdural metastatic lesions, need to have stopped it, at least for 4 weeks or until there are no signs of brain metastasis and/or symptoms must have stabilized for at least 4 weeks, if local treatment has been completed. Enhanced computed tomography (CT) or magnetic resonance imaging (MRI) images during screening are compared with those performed at least 4 weeks earlier to determine radiological stability. * Patients with severe vascular diseases, including unstable angina, myocardial infarction, or severe arrhythmia in the past 6 months * History of HIV infection or active chronic hepatitis B or C * Patients with other serious infectious diseases * Patients positive for ER/PR/HER-2 positive * Patients with allogeneic organ transplants requiring immunosuppressive therapy * History of other malignant tumors within 5 years, except for cured cervical carcinoma in situ or basal cell carcinoma of the skin * Other destabilizing factors that may interfere with patients or have an impact on the trial results * Allergic to target drugs or allergic to related drugs applied in the trial * Pregnant or lactating women